Even though I'm off today I, like a lot of folks, couldn't help checking my landline voicemail at work. And much to my surprise one of the messages was from Mark Gottlieb, the Chief Compliance Officer at Visium Asset Mgt. I referred to him in yesterday's post.
As I said, Visium is the New York hedge fund that's taken a 10 percent stake in Dendreon . Gottlieb said they've decided not to comment on their position, but indicated they might be interested in talking to the press at some point. In the meantime, he wished me luck in my ongoing coverage of DNDN. Thanks, I guess. At least he was good enough to call back. There you go.
Questions? Comments? Pharma@cnbc.com